Cleared Dual Track

K231381 - Xpert Xpress MVP (FDA 510(k) Clearance)

Also includes:
GeneXpert Xpress System
Oct 2023
Decision
160d
Days
Class 2
Risk

K231381 is an FDA 510(k) clearance for the Xpert Xpress MVP. This device is classified as a Vaginitis And Bacterial Vaginosis Nucleic Acid Detection System (Class II - Special Controls, product code PQA).

Submitted by Cepheid (Sunnyvale, US). The FDA issued a Cleared decision on October 19, 2023, 160 days after receiving the submission on May 12, 2023.

This device falls under the Microbiology FDA review panel. Regulated under 21 CFR 866.3975. A Vaginitis And Bacterial Vaginosis Nucleic Acid Detection System Is A Qualitative In Vitro Diagnostic Device For The Direct Detection Of Nucleic Acid Sequences From Microorganisms Associated With Vaginitis Or Bacterial Vaginosis. The Device Is Indicated For Individuals With Signs And Symptoms Of Vaginitis Or Bacterial Vaginosis And Aids In The Diagnosis Of These Vaginal Infections..

Submission Details

510(k) Number K231381 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 12, 2023
Decision Date October 19, 2023
Days to Decision 160 days
Submission Type Dual Track
Review Panel Microbiology (MI)
Summary Summary PDF

Device Classification

Product Code PQA — Vaginitis And Bacterial Vaginosis Nucleic Acid Detection System
Device Class Class II - Special Controls
CFR Regulation 21 CFR 866.3975
Definition A Vaginitis And Bacterial Vaginosis Nucleic Acid Detection System Is A Qualitative In Vitro Diagnostic Device For The Direct Detection Of Nucleic Acid Sequences From Microorganisms Associated With Vaginitis Or Bacterial Vaginosis. The Device Is Indicated For Individuals With Signs And Symptoms Of Vaginitis Or Bacterial Vaginosis And Aids In The Diagnosis Of These Vaginal Infections.